<?xml version='1.0' encoding='utf-8'?>
<document id="27105861"><sentence text="Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin."><entity charOffset="51-59" id="DDI-PubMed.27105861.s1.e0" text="androgen" /><entity charOffset="103-115" id="DDI-PubMed.27105861.s1.e1" text="itraconazole" /><entity charOffset="117-125" id="DDI-PubMed.27105861.s1.e2" text="rifampin" /><entity charOffset="127-137" id="DDI-PubMed.27105861.s1.e3" text="probenecid" /><entity charOffset="139-148" id="DDI-PubMed.27105861.s1.e4" text="celecoxib" /><entity charOffset="153-165" id="DDI-PubMed.27105861.s1.e5" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e0" e2="DDI-PubMed.27105861.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e0" e2="DDI-PubMed.27105861.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e0" e2="DDI-PubMed.27105861.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e0" e2="DDI-PubMed.27105861.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e0" e2="DDI-PubMed.27105861.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e0" e2="DDI-PubMed.27105861.s1.e5" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e1" e2="DDI-PubMed.27105861.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e1" e2="DDI-PubMed.27105861.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e1" e2="DDI-PubMed.27105861.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e1" e2="DDI-PubMed.27105861.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e1" e2="DDI-PubMed.27105861.s1.e5" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e2" e2="DDI-PubMed.27105861.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e2" e2="DDI-PubMed.27105861.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e2" e2="DDI-PubMed.27105861.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e2" e2="DDI-PubMed.27105861.s1.e5" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e3" e2="DDI-PubMed.27105861.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e3" e2="DDI-PubMed.27105861.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e3" e2="DDI-PubMed.27105861.s1.e5" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e4" e2="DDI-PubMed.27105861.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27105861.s1.e4" e2="DDI-PubMed.27105861.s1.e5" /></sentence><sentence text="GTx-024 (also known as enobosarm) is a first in class selective androgen receptor modulator being developed for diverse indications in oncology"><entity charOffset="64-72" id="DDI-PubMed.27105861.s2.e0" text="androgen" /></sentence><sentence text=" Preclinical studies of GTx-024 supported the evaluation of several potential drug-drug interactions in a clinical setting" /><sentence text=" A series of open-label Phase I GTx-024 drug-drug interaction studies were designed to interrogate potential interactions with CYP3A4 inhibitor (itraconazole), a CYP3A4 inducer (rifampin), a pan-UGT inhibitor (probenecid), a CYP2C9 substrate (celecoxib) and a BCRP substrate (rosuvastatin)"><entity charOffset="145-157" id="DDI-PubMed.27105861.s4.e0" text="itraconazole" /><entity charOffset="178-186" id="DDI-PubMed.27105861.s4.e1" text="rifampin" /><entity charOffset="210-220" id="DDI-PubMed.27105861.s4.e2" text="probenecid" /><entity charOffset="243-252" id="DDI-PubMed.27105861.s4.e3" text="celecoxib" /><entity charOffset="276-288" id="DDI-PubMed.27105861.s4.e4" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e0" e2="DDI-PubMed.27105861.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e0" e2="DDI-PubMed.27105861.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e0" e2="DDI-PubMed.27105861.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e0" e2="DDI-PubMed.27105861.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e0" e2="DDI-PubMed.27105861.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e1" e2="DDI-PubMed.27105861.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e1" e2="DDI-PubMed.27105861.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e1" e2="DDI-PubMed.27105861.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e1" e2="DDI-PubMed.27105861.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e2" e2="DDI-PubMed.27105861.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e2" e2="DDI-PubMed.27105861.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e2" e2="DDI-PubMed.27105861.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e3" e2="DDI-PubMed.27105861.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27105861.s4.e3" e2="DDI-PubMed.27105861.s4.e4" /></sentence><sentence text=" The plasma pharmacokinetics of GTx-024, its major metabolite (GTx-024 glucuronide), and each substrate were characterized in detail" /><sentence text=" Itraconazole administration had no effect on GTx-024 pharmacokinetics"><entity charOffset="1-13" id="DDI-PubMed.27105861.s6.e0" text="Itraconazole" /></sentence><sentence text=" Likewise, GTx-024 administration did not significantly change the pharmacokinetics of celecoxib or rosuvastatin"><entity charOffset="87-96" id="DDI-PubMed.27105861.s7.e0" text="celecoxib" /><entity charOffset="100-112" id="DDI-PubMed.27105861.s7.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.27105861.s7.e0" e2="DDI-PubMed.27105861.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27105861.s7.e0" e2="DDI-PubMed.27105861.s7.e1" /></sentence><sentence text=" Rifampin administration had the largest impact on GTx-024 pharmacokinetics of any co-administered agent and reduced the maximal plasma concentration (Cmax) by 23 % and the area under the curve (AUC∞) by 43 %"><entity charOffset="1-9" id="DDI-PubMed.27105861.s8.e0" text="Rifampin" /></sentence><sentence text=" Probenecid had a complex interaction with GTx-024 whereby both GTx-024 plasma levels and GTx-024 glucuronide plasma levels (AUC∞) were increased by co-administration of the UGT inhibitor (50 and 112 %, respectively)"><entity charOffset="1-11" id="DDI-PubMed.27105861.s9.e0" text="Probenecid" /></sentence><sentence text=" Overall, GTx-024 was well tolerated and poses very little risk of generating clinically relevant drug-drug interactions" /><sentence text="" /></document>